1.Børlum Kristensen, F, Husereau, D, Huić, M, et al. (2019) Identifying the need for good practices in health technology assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value Health 22: 13–20.
2.Banta, HD (2003) The development of health technology assessment. Health Policy 63: 121–132.
3.Bielecki, A, Nieszporska, S (2017) The proposal of philosophical basis of the health care system. Med Health Care Philos 20: 23–35.
4.Velasco Garrido, M, Børlum Kristensen, F, Palmhoj Nielsen, C, Busse, R (2008) Health technology assessment and health policy-making in Europe. Copenhagen, Denmark: WHO Regional Office for Europe.
5.Angelis, A, Lange, A, Kavanos, P (2018) Using health technology assessment to assess value of new medicines: Results of a systematic review and expert consultation across eight European countries. Eur J Health Econ 19: 123–152.
6.Lysdahl, KB, Mozygemba, K, Burns, JBC, Brönneke, JB, Hofmann, B, eds. (2016) . http://www.integrate-hta.eu/downloads/.
7.Bertram, MY, Lauer, JA, De Joncheere, K, et al. (2016) Cost-effectiveness thresholds: Pros and cons. Bull World Health Organ 94: 925–930.
8.Abrishami, P, Oortwijn, W, Hofmann, B (2017) Ethics in HTA: Examining the “need for expansion.” Int J Health Policy Manag 6: 551–553.
9.Kaló, Z, Gheorghe, A, Huic, M, Csanádi, M, Borlum Kristensen, F (2016) HTA implementation roadmap in Central and Eastern European countries. Health Econ 25, S1:179–192.
10.Goetghebeur, M, Wagner, M, Samaha, D, et al. (2017) Exploring values of health technology assessment agencies using reflective multicriteria and rare disease case. Int J Technol Assess Health Care 33: 1–17.
11.Löblová, O (2018) What has health technology assessment ever done for us? J Health Services Res Policy 23: 134–136.
12.Haycox, A (2016) Why Cancer? PharmacoEconomics 34: 625–627.
13.Hofmann, B, Bond, K, Sandman, L (2018) Evaluating facts and facting evaluations: On the fact-value relationship in HTA. J Eval Clin Pract 24: 957–965.
14.Juzwishin, DWM (2005) Educating publics and policy makers: Epistemic communities and the politics of evidence-based reform in Alberta and Saskatchewan. . Alberta: University of Alberta, , p. 55.
15.Hoedemaekers, R, Oortwijn, W (2003) Problematic notions in Dutch health care package decisions. Health Care Anal 11: 287–294.
16.Kleinhout-Vliek, T, de Bont, A, Boer, B (2017) The bare necessities? A realist review of necessity argumentations used in health care coverage decisions. Health Policy 121: 731–744.
17.Hoffman, B (2013) Priority setting in health care: Trends and models from Scandinavian experiences. Med Health Care Philos 16: 349–356.
18.Heintz, E, Arnberg, K, Levin, LA, Liliemark, J, Davidson, T (2014) The impact of health economic evaluations in Sweden. Z Evid Fortbild Qual Gesundhwes 108: 375–382.
19.Matar, A, Hansson, MG, Höglund, AT (2018) “A perfect society”— Swedish policymakers’ ethical and social views on preconception expanded carrier screening. J Community Genet https://doi.org/10.1007/s12687-018-0389-x.
20.Höglund, AT, Falkenström, E (2018) The status of ethics in Swedish health care management: A qualitative study. BMC Health Serv Res 18: 608.
21.Angelis, A, Kavanos, P, Montibeller, G (2017) Resource allocation and priority setting in health care: A multi-criteria decision analysis problem of value? Glob Policy 8: 76–83.
22.Oortwijn, W, van der Wilt, GJ, on behalf of the Special Interest Group on HTA and Ethics (2016) Challenges in contemporary HTA. A view from the outside. Int J Technol Assess Health Care 32: 1–2.
23.Oortwijn, W, Determann, D, Schiffers, K, Tan, SS, van der Tuin, J (2017) Towards integrated health technology assessment for improving decision-making in selected countries. Value Health 20: 1121–1130.
24.Klein, R, Day, P, Redmayne, S (1996) Managing scarcity: Priority setting and rationing in the National Health Service. Buckingham: Open University Press, .
25.Baltussen, R, Jansen, MP, Mikkelsen, E, et al. (2016) Priority setting for universal health coverage: We need evidence-informed deliberative processes, not just more evidence on cost-effectiveness. Int J Health Policy Manag 5: 615–618.